249 related articles for article (PubMed ID: 31181069)
1. Influence of genetic factors on long-term treatment related neurocognitive complications, and on anxiety and depression in survivors of childhood acute lymphoblastic leukemia: The Petale study.
Petrykey K; Lippé S; Robaey P; Sultan S; Laniel J; Drouin S; Bertout L; Beaulieu P; St-Onge P; Boulet-Craig A; Rezgui A; Yasui Y; Sapkota Y; Krull KR; Hudson MM; Laverdière C; Sinnett D; Krajinovic M
PLoS One; 2019; 14(6):e0217314. PubMed ID: 31181069
[TBL] [Abstract][Full Text] [Related]
2. Genetic Factors and Long-term Treatment-Related Neurocognitive Deficits, Anxiety, and Depression in Childhood Leukemia Survivors: An Exome-Wide Association Study.
Petrykey K; Lippé S; Sultan S; Robaey P; Drouin S; Affret-Bertout L; Beaulieu P; St-Onge P; Baedke JL; Yasui Y; Hudson MM; Laverdière C; Sinnett D; Krajinovic M
Cancer Epidemiol Biomarkers Prev; 2024 Feb; 33(2):234-243. PubMed ID: 38051303
[TBL] [Abstract][Full Text] [Related]
3. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.
Radtke S; Zolk O; Renner B; Paulides M; Zimmermann M; Möricke A; Stanulla M; Schrappe M; Langer T
Blood; 2013 Jun; 121(26):5145-53. PubMed ID: 23652803
[TBL] [Abstract][Full Text] [Related]
4. Genetic factors contributing to late adverse musculoskeletal effects in childhood acute lymphoblastic leukemia survivors.
Shalmiev A; Nadeau G; Aaron M; Ouimet-Grennan E; Drouin S; Bertout L; Beaulieu P; St-Onge P; Veilleux LN; Rauch F; Rezgui A; Petrykey K; Laverdière C; Sinnett D; Alos N; Krajinovic M
Pharmacogenomics J; 2022 Feb; 22(1):19-24. PubMed ID: 34446917
[TBL] [Abstract][Full Text] [Related]
5. Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis.
Cheung YT; Sabin ND; Reddick WE; Bhojwani D; Liu W; Brinkman TM; Glass JO; Hwang SN; Srivastava D; Pui CH; Robison LL; Hudson MM; Krull KR
Lancet Haematol; 2016 Oct; 3(10):e456-e466. PubMed ID: 27658980
[TBL] [Abstract][Full Text] [Related]
6. Neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on contemporary treatment protocols: A systematic review.
Cheung YT; Krull KR
Neurosci Biobehav Rev; 2015 Jun; 53():108-20. PubMed ID: 25857254
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
[TBL] [Abstract][Full Text] [Related]
8. Genetic factors in treatment-related cardiovascular complications in survivors of childhood acute lymphoblastic leukemia.
Petrykey K; Rezgui AM; Guern ML; Beaulieu P; St-Onge P; Drouin S; Bertout L; Wang F; Baedke JL; Yasui Y; Hudson MM; Raboisson MJ; Laverdière C; Sinnett D; Andelfinger GU; Krajinovic M
Pharmacogenomics; 2021 Sep; 22(14):885-901. PubMed ID: 34505544
[No Abstract] [Full Text] [Related]
9. Pharmacoepigenetics in childhood acute lymphoblastic leukemia: involvement of miRNA polymorphisms in hepatotoxicity.
Gutierrez-Camino A; Umerez M; Santos B; Martin-Guerrero I; García de Andoin N; Sastre A; Navajas A; Astigarraga I; Garcia-Orad A
Epigenomics; 2018 Apr; 10(4):409-417. PubMed ID: 29569486
[TBL] [Abstract][Full Text] [Related]
10. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.
Treviño LR; Shimasaki N; Yang W; Panetta JC; Cheng C; Pei D; Chan D; Sparreboom A; Giacomini KM; Pui CH; Evans WE; Relling MV
J Clin Oncol; 2009 Dec; 27(35):5972-8. PubMed ID: 19901119
[TBL] [Abstract][Full Text] [Related]
11. Evolution of neurocognitive function in long-term survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only.
Liu W; Cheung YT; Conklin HM; Jacola LM; Srivastava D; Nolan VG; Zhang H; Gurney JG; Huang IC; Robison LL; Pui CH; Hudson MM; Krull KR
J Cancer Surviv; 2018 Jun; 12(3):398-406. PubMed ID: 29484542
[TBL] [Abstract][Full Text] [Related]
12. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.
Ramsey LB; Bruun GH; Yang W; Treviño LR; Vattathil S; Scheet P; Cheng C; Rosner GL; Giacomini KM; Fan Y; Sparreboom A; Mikkelsen TS; Corydon TJ; Pui CH; Evans WE; Relling MV
Genome Res; 2012 Jan; 22(1):1-8. PubMed ID: 22147369
[TBL] [Abstract][Full Text] [Related]
13. Identification of genetic association between cardiorespiratory fitness and the trainability genes in childhood acute lymphoblastic leukemia survivors.
Caru M; Petrykey K; Drouin S; Beaulieu P; St-Onge P; Lemay V; Bertout L; Laverdiere C; Andelfinger G; Krajinovic M; Sinnett D; Curnier D
BMC Cancer; 2019 May; 19(1):443. PubMed ID: 31088516
[TBL] [Abstract][Full Text] [Related]
14. Impact of sleep, fatigue, and systemic inflammation on neurocognitive and behavioral outcomes in long-term survivors of childhood acute lymphoblastic leukemia.
Cheung YT; Brinkman TM; Mulrooney DA; Mzayek Y; Liu W; Banerjee P; Panoskaltsis-Mortari A; Srivastava D; Pui CH; Robison LL; Hudson MM; Krull KR
Cancer; 2017 Sep; 123(17):3410-3419. PubMed ID: 28452142
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal Assessment of Neurocognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia Treated on a Contemporary Chemotherapy Protocol.
Jacola LM; Krull KR; Pui CH; Pei D; Cheng C; Reddick WE; Conklin HM
J Clin Oncol; 2016 Apr; 34(11):1239-47. PubMed ID: 26858334
[TBL] [Abstract][Full Text] [Related]
16. Folate pathway polymorphisms predict deficits in attention and processing speed after childhood leukemia therapy.
Kamdar KY; Krull KR; El-Zein RA; Brouwers P; Potter BS; Harris LL; Holm S; Dreyer Z; Scaglia F; Etzel CJ; Bondy M; Okcu MF
Pediatr Blood Cancer; 2011 Sep; 57(3):454-60. PubMed ID: 21618410
[TBL] [Abstract][Full Text] [Related]
17. CNS late-effects after ALL therapy in childhood. Part III: neuropsychological performance in long-term survivors of childhood ALL: impairments of concentration, attention, and memory.
Langer T; Martus P; Ottensmeier H; Hertzberg H; Beck JD; Meier W
Med Pediatr Oncol; 2002 May; 38(5):320-8. PubMed ID: 11979456
[TBL] [Abstract][Full Text] [Related]
18. Cerebral glucose metabolism in survivors of childhood acute lymphoblastic leukemia.
Kähkönen M; Metsähonkala L; Minn H; Utriainen T; Korhonen T; Norvasuo-Heilä MK; Harila-Saari A; Aärimaa T; Suhonen-Polvi H; Ruotsalainen U; Solin O; Salmi TT
Cancer; 2000 Feb; 88(3):693-700. PubMed ID: 10649265
[TBL] [Abstract][Full Text] [Related]
19. Genomic determinants of long-term cardiometabolic complications in childhood acute lymphoblastic leukemia survivors.
England J; Drouin S; Beaulieu P; St-Onge P; Krajinovic M; Laverdière C; Levy E; Marcil V; Sinnett D
BMC Cancer; 2017 Nov; 17(1):751. PubMed ID: 29126409
[TBL] [Abstract][Full Text] [Related]
20. The PETALE study: Late adverse effects and biomarkers in childhood acute lymphoblastic leukemia survivors.
Marcoux S; Drouin S; Laverdière C; Alos N; Andelfinger GU; Bertout L; Curnier D; Friedrich MG; Kritikou EA; Lefebvre G; Levy E; Lippé S; Marcil V; Raboisson MJ; Rauch F; Robaey P; Samoilenko M; Séguin C; Sultan S; Krajinovic M; Sinnett D
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27917589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
